Brief: Orchestra Biomed To Receive Up To $21 Million In Proceeds From Acquisition Of Vivasure By Haemonetics
12/01/2026 14:03
Jan 12 (Reuters) - Haemonetics Corp HAE.N: ORCHESTRA BIOMED TO RECEIVE UP TO $21 MILLION IN PROCEEDS FROM ACQUISITION OF VIVASURE BY HAEMONETICS Source text: ID:nGNX269v3M Further company coverage: HAE.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Haemonetics
See all newsBrief: Haemonetics Announces FDA Approval Of Perqseal® Elite Vascular Closure System
Haemonetics says FDA clears vascular closure device
US STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Haemonetics surges as CSL plans to move all US plasma centers to its devices